Diabetes Articles
  • Sign Up
FacebookTwitterDiggStumbleuponGoogle BookmarksRedditLinkedinPinterest

Scientists uncover new mechanism that reduces risk of type 2 diabetes, cardiovascular disease (I)

Findings could lead to next generation of improved therapies
In a joint study, scientists from The Scripps Research Institute and the Dana-Farber Cancer Institute at Harvard University have uncovered a novel mechanism that dramatically increases insulin sensitivity and reduces the risk of developing type 2 diabetes and cardiovascular disease.

These findings offer a potent new target in the continuing search for new and improved anti-diabetic treatments. Currently, nearly 24 million children and adults in the United States have some form of the disease, according to the America Diabetes Association.

The new study, which focuses on controlling a fat-regulating protein known as PPARy, was published July 22, 2010, in the journal Nature (Volume 466, Issue 7304).

"The field has become interested in finding drugs that can promote increased insulin sensitization but not activate the classical fat cell generating pathway of PPARγ," said Patrick R. Griffin, chairman of the Department of Molecular Therapeutics at Scripps Florida who headed up the Scripps Research part of the study. "We examined the mechanism of action of compounds that bind to PPARγ that improve insulin sensitivity but have minimal induction of fat. It was clear from the studies that these compounds have a unique but overlapping mechanism with the class of drugs used clinically that target PPARγ."

Adipose or fat tissue lies at the center of the metabolic syndrome, a cluster of risk factors that increases the possibility of type 2 diabetes, as well as stroke, coronary artery disease, even certain cancers. Of those risk factors, excessive body fat is considered the most problematic. PPARγ can be considered the master gene of fat cell biology because it drives the conversion of cellular precursors into fat cells.

The collaborative studies showed obesity causes a modification on PPARγ that leads to alterations in the expression of a number of genes, including a reduction in the production of an insulin-sensitizing protein (adiponectin). This leads to an increase in insulin resistance. The reprogramming of genes controlled by PPARγ occurs when it undergoes phosphorylation (a phosphate group is added to a protein) by the cdk5 kinase, an enzyme that is involved in a number of important sensory pathways and that can be activated by pro-inflammatory proteins.

The scientists were able to use both full and partial agonists (compounds that activate a cellular response) to reverse these phosphorylation effects and improve the production of adiponectin. These results strongly suggest that cdk5-mediated phosphorylation is involved in the development of insulin-resistance and open the door to a novel opportunity for creating an improved generation of anti-diabetic drugs.

Source: Scripps Research Institute
(to be continued)

Labels: diabetes general

Read Full Article

Find out if you qualify for discount Diabetic testing supplies, free offers or other running discounts at this time.


  1. First Name*
    Enter first name
  2. Last Name*
    Enter last name
  3. Phone*
    Enter valid US phone number
  4. E-mail*
    Enter email address



By submitting this form I authorize to be contacted by telephone. Please be assured that we value and protect your privacy. Co-Pays and Deductibles may apply.

About The Diabetes Network

The Diabetes Network was developed with the idea that people living with diabetes needed a central place to go for resources as well as get ideas, suggestions and encouragement. We have put a lot of effort into this website to make it easy and fun to navigate as well as informative so that you can have a voice when it comes to managing your diabetes. Please let us know how we can improve this website to better suit your needs.

More about our Mission

We're on a mission to make the healthcare community more technologically advanced than ever before. This website adapts to fit your tablet, iPad®, iPhone®, Android® or other smartphone. Just one of the ways we are working to make life easier for those living with Diabetes. Learn More...